NCT00332046已完成1 期
A Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Parallel Group, fMRI Study Comparing BOLD Activation Patterns Before and After 12 Weeks of Treatment With Placebo, Comparator and GW679769 in Subjects With Social Anxiety Disorder (SAD).
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 57
- 试验地点
- 2
- 主要终点
- Change in images of the brain, when stimulated, after once daily dosing for 12 weeks with GW679769, comparator or placebo in subjects with SAD.
研究概览
简要总结
Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core symptoms of the disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Change in images of the brain, when stimulated, after once daily dosing for 12 weeks with GW679769, comparator or placebo in subjects with SAD.
次要结局
- Blood levels of GW679769 and comparator at the Week 1 and Week 12 Change in clinical rating scales from baseline to Week 12 Safety & tolerability
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.Healthy SubjectsNCT00424697GlaxoSmithKline26
已完成
3 期
Experimental Medication For the Treatment of Generalized Anxiety DisorderAnxiety DisorderNCT00097708Jazz Pharmaceuticals511
已完成
3 期
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety DisorderAnxiety DisorderNCT00236015Cephalon880
已完成
3 期
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety DisorderGeneralized Anxiety DisorderNCT00236067Cephalon440
已完成
3 期
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety DisorderGeneralized Anxiety DisorderNCT00236054Cephalon440
